The therapeutic potential of VEGF inhibition in diabetic microvascular complications

Gemma Tremolada, Rosangela Lattanzio, Gabriella Mazzolari, Gianpaolo Zerbini

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus. The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin). According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.

Original languageEnglish
Pages (from-to)393-398
Number of pages6
JournalAmerican Journal of Cardiovascular Drugs
Volume7
Issue number6
Publication statusPublished - 2007

Fingerprint

Diabetes Complications
Vascular Endothelial Growth Factor A
Therapeutics
4'-N-benzoylstaurosporine
Vascular Endothelial Growth Factor Receptor
Macular Edema
Diabetic Neuropathies
Incidence
Macular Degeneration
Diabetic Nephropathies
Diabetic Retinopathy
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

The therapeutic potential of VEGF inhibition in diabetic microvascular complications. / Tremolada, Gemma; Lattanzio, Rosangela; Mazzolari, Gabriella; Zerbini, Gianpaolo.

In: American Journal of Cardiovascular Drugs, Vol. 7, No. 6, 2007, p. 393-398.

Research output: Contribution to journalArticle

Tremolada, Gemma ; Lattanzio, Rosangela ; Mazzolari, Gabriella ; Zerbini, Gianpaolo. / The therapeutic potential of VEGF inhibition in diabetic microvascular complications. In: American Journal of Cardiovascular Drugs. 2007 ; Vol. 7, No. 6. pp. 393-398.
@article{09f057dbd864420a815e2690d923dec8,
title = "The therapeutic potential of VEGF inhibition in diabetic microvascular complications",
abstract = "During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus. The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin). According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.",
author = "Gemma Tremolada and Rosangela Lattanzio and Gabriella Mazzolari and Gianpaolo Zerbini",
year = "2007",
language = "English",
volume = "7",
pages = "393--398",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - The therapeutic potential of VEGF inhibition in diabetic microvascular complications

AU - Tremolada, Gemma

AU - Lattanzio, Rosangela

AU - Mazzolari, Gabriella

AU - Zerbini, Gianpaolo

PY - 2007

Y1 - 2007

N2 - During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus. The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin). According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.

AB - During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus. The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin). According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.

UR - http://www.scopus.com/inward/record.url?scp=37149005811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149005811&partnerID=8YFLogxK

M3 - Article

C2 - 18076206

AN - SCOPUS:37149005811

VL - 7

SP - 393

EP - 398

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 6

ER -